Advertisement
Advertisement

INMB

INMB logo

INmune Bio Inc. Common stock

1.58
USD
Sponsored
+0.02
+1.15%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

1.58

0.00
+0.13%

INMB Earnings Reports

Positive Surprise Ratio

INMB beat 15 of 27 last estimates.

56%

Next Report

Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.24
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
-40.00%

INmune Bio Inc. Common stock earnings per share and revenue

On Oct 30, 2025, INMB reported earnings of -0.24 USD per share (EPS) for Q3 25, beating the estimate of -0.33 USD, resulting in a 27.60% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.78% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, INmune Bio Inc. Common stock reported EPS of -$0.24, beating estimates by 27.6%, and revenue of $0.00, 0% as expectations.
The stock price moved up 5.78%, changed from $1.73 before the earnings release to $1.83 the day after.
The next earning report is scheduled for Feb 26, 2026.
Based on 6 analysts, INmune Bio Inc. Common stock is expected to report EPS of -$0.24 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement